Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?

  • D. Waitzberg
  • , F. Guarner
  • , I. Hojsak
  • , Gianluca Ianiro
  • , D. B. Polk
  • , H. Sokol*
  • *Autore corrispondente per questo lavoro
  • Universidade de São Paulo
  • Teknon Medical Centre
  • University of Zagreb
  • Paris Center for Microbiome Médicine (PaCeMM) FHU
  • Sorbonne Université
  • Université Paris-Saclay

Risultato della ricerca: Contributo in rivista › Recensione

Abstract

Dysbiosis corresponds to the disruption of a formerly stable, functionally complete microbiota. In the gut, this imbalance can lead to adverse health outcomes in both the short and long terms, with a potential increase in the lifetime risks of various noncommunicable diseases and disorders such as atopy (like asthma), inflammatory bowel disease, neurological disorders, and even behavioural and psychological disorders. Although antibiotics are highly effective in reducing morbidity and mortality in infectious diseases, antibiotic-associated diarrhoea is a common, non-negligible clinical sign of gut dysbiosis (and the only visible one). Re-establishment of a normal (functional) gut microbiota is promoted by completion of the clinically indicated course of antibiotics, the removal of any other perturbing external factors, the passage of time (i.e. recovery through the microbiota’s natural resilience), appropriate nutritional support, and—in selected cases—the addition of probiotics. Systematic reviews and meta-analyses of clinical trials have confirmed the strain-specific efficacy of some probiotics (notably the yeast Saccharomyces boulardii CNCM I-745 and the bacterium Lactobacillus rhamnosus GG) in the treatment and/or prevention of antibiotic-associated diarrhoea in children and in adults. Unusually for a probiotic, S. boulardii is a eukaryote and is not therefore directly affected by antibiotics—making it suitable for administration in cases of antibiotic-associated diarrhoea. A robust body of evidence from clinical trials and meta-analyses shows that the timely administration of an adequately dosed probiotic (upon initiation of antibiotic treatment or within 48 h) can help to prevent or resolve the consequences of antibiotic-associated dysbiosis (such as diarrhoea) and promote the resilience of the gut microbiota and a return to the pre-antibiotic state. A focus on the prescription of evidence-based, adequately dosed probiotics should help to limit unjustified and potentially ineffective self-medication.
Lingua originaleInglese
pagine (da-a)901-914
Numero di pagine14
RivistaAdvances in Therapy
Volume41
Numero di pubblicazione3
DOI
Stato di pubblicazionePubblicato - 2024

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

  1. SDG 3 - Salute e benessere
    SDG 3 Salute e benessere

All Science Journal Classification (ASJC) codes

  • Farmacologia (medica)

Keywords

  • Antibiotics
  • Diarrhoea
  • Dose
  • Dysbiosis
  • Probiotics
  • Strain-specificity

Fingerprint

Entra nei temi di ricerca di 'Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?'. Insieme formano una fingerprint unica.

Cita questo